Forums
| << Previous thread | Next thread >> |
 NHS restriction on dementia drugs. |
| Author | Post |
| Pam S |
|
||
  Joined: Mon Jan 22 2007, 05:23AM Posts: 25 |
The Alzheimers Society is today - Friday 27th April 2007 submitting to the high court the serious flaws in the way the National Institute for Health and Clinical Excellence (NICE) reached its decision to restrict access to dementia drugs on the NHS. Neil Hunt, chief executive of the Alzheimers Society says, 'The evidence we are presenting today highlights serious flaws in the process NICE have used. The decision is a blow for millions of people already devasted by Alzheimers disease. We have been left with no choice but to champion the rights of people with dementia and their carers in the high court.' Campaigners are now waiting for a court date for arguments to be heard. Should access to dementia drugs be restricted on the NHS? [ Edited Fri Apr 27 2007, 01:06PM ] |
||
| Back to top |
|
| Erica |
|
||
|
Joined: Fri Mar 02 2007, 04:11AM Posts: 14 |
It seems there has been new research which goes against the National Institute for Health and Clinical Excellence (NICE) ruling. This new investigation into the effects of cholinesterase inhibitors on the human brain have proven the positive outcomes for users with dementia, causing medical experts to question Nice's earlier decision to not provide the drugs. Those with dementia, prescribed with cholinesterase treatments saw a 70% reduction in the amount of plaque-causing amyloids which hasten the onset of diseases like Alzheimer's. NICE's decision is set to be challenged in court. |
||
| Back to top |
|
| Erica |
|
||
|
Joined: Fri Mar 02 2007, 04:11AM Posts: 14 |
NICE challenged over Alzheimer's drugs. The government’s medicines watchdog was accused today of “irrationally and unlawfully” withholding drugs which could help thousands of people suffering from early-stage dementia. Two pharmaceutical companies and a charity are challenging a controversial decision taken by the National Institute of Clinical Excellence (NICE) to restrict the use of their drugs to people with middle-stage dementia only. It is the first time the watchdog has faced a legal challenge Opening the four-day case, David Pannick QC, representing Eisai, licensed holder of the drug Aricept, said Alzheimer’s was an appalling disease which was wrecking lives. Yet there were drugs which could “buy time and quality of life” for sufferers with mild symptoms. For more information : Time Online |
||
| Back to top |
|
| Erica |
|
||
|
Joined: Fri Mar 02 2007, 04:11AM Posts: 14 |
'We paid for dementia diagnosis' Dementia services need to be urgently addressed if they are to meet future demand, a watchdog has said. The National Audit Office has criticised the NHS for lagging behind other countries when it comes to early diagnosis. BBC News |
||
| Back to top |
|
| Erica |
|
||
|
Joined: Fri Mar 02 2007, 04:11AM Posts: 14 |
Call for improved dementia care. The NHS must urgently address failings in dementia care if it is to cope with future demands, a watchdog has said. The number of people with dementia is expected to rise by a third in the next 15 years, but the National Audit Office said it was not enough of a priority. The report said England lagged behind other European countries over early diagnosis and access to drugs. BBC News |
||
| Back to top |
|
| Pam S |
|
||
|
Joined: Mon Jan 22 2007, 05:23AM Posts: 25 |
FDA approves patch to treat dementia in Alzheimer’s and Parkinson’s patients The Associated Press WASHINGTON | The first skin patch to treat Alzheimer’s patients has gained federal approval, a drug company said Monday. The drug in the patch, called Exelon or rivastigmine, is the same as that is available in capsule form, but the patch provides a regular and continuous dose throughout the day, according to Novartis Pharmaceuticals Corp. Because the drug enters the bloodstream directly, the patch also eliminates some of the gastrointestinal side effects that are associated with the drug when swallowed. The drug is meant to treat the symptoms of mild to moderate dementia in patients with Alzheimer’s disease. It also won Food and Drug Administration approval to treat patients with mild to moderate dementia from Parkinson’s disease, Novartis said. About 4.5 million Americans have Alzheimer’s. As the disease progresses, it robs patients of their memories and changes how they both think and behave. It is ultimately fatal. Rivastigmine is not a cure. It inhibits the breakdown of a chemical in the brain called acetylcholine, which is thought to be important to learning and memory. |
||
| Back to top |
|
| Moderators: Head Admin, Barry, Steve, Pam S, James, Steve_M, Tim, Nick, Rajpal |
Powered by e107 Forum System
 Liverpool Personal Services Society (Inc.) A company limited by guarantee, registered in England and Wales (214077) A charity registered in England and Wales (224469) and in Scotland (SC038925) DISCLAIMER By using this website you are agreeing to be bound by PSS Terms and Conditions. For the full terms and conditions Click Here |
Quick Links
Search Dementia Centre
Dementia Café
Random Albums
| Dementia Conference Gallery 2 |
|
| Pictures: 8 |
| Skills For Care Accolade 2009 |
|
| Pictures: 12 |
| Great North West Care Awards |
|
| Pictures: 10 |
Accessibility
Support Line
Headlines
| » | Dementia: A family's story
"It is role reversal, Nan used to look after us, and now it is the other way around" |
| » | Cutting the risk of dementia
Experts set out the measures you can take to make the onset of dementia less likely |
Date published: Mon, 05 Jul 2010 10:18:13 GMT
Details
| » | Dementia Warning Signs Identified in Type 2 Diabetics: Study
Title: Dementia Warning Signs Identified in Type 2 Diabetics: StudyCategory: Health NewsCreated: 9/8 ... |
| » | Memory Loss May Be More Common in Men
Title: Memory Loss May Be More Common in MenCategory: Health NewsCreated: 9/8/2010 10:34:00 AMLast E ... |
Date published: Thu, 9 Sep 2010 00:00:00 PDT
Details
Welcome
Click A Flag to Translate
